Reversible Inhibitors Of Monoamine Antidepressants Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type (Nonselective MAO-A Inhibitors, Selective MAO-B Inhibitors, Nonselective MAO-B Inhibitors); Application (Depression Treatment, Parkinson's Disease Treatment, Others), and Geography

Report Code: TIPRE00018776 | No. of Pages: 150 | Category: Biotechnology | Status: Upcoming
Covid
MARKET INTRODUCTION

A reversible inhibitor of monoamine oxidase A (RIMA) is a subclass of monoamine oxidase inhibitors MAOIs that inhibit reversibly and selectively the MAO-A enzyme. RIMA is used clinically to treat depression and dysthymia. Due to its reversibility, it is safe to use in single-drug overdose than the older, irreversible MAOIs and weaker in increasing the monoamines important in depressive disorder.

MARKET DYNAMICS

The reversible inhibitors of monoamine antidepressants market growth are estimated to grow due to increasing incidences of neurological disorders, growing pharmaceutical production, and growing pharmaceutical companies' investments for product developments. In comparison, the market is expected to grow opportunities owing to developments in the pharmaceutical industry in emerging regions.

MARKET SCOPE

The "Reversible Inhibitors of Monoamine Antidepressants Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of reversible inhibitors of monoamine antidepressants market with detailed market segmentation by type, and application. The reversible inhibitors of monoamine antidepressants market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in reversible inhibitors of monoamine antidepressants market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The reversible inhibitors of monoamine antidepressants market is segmented on the basis of, type, and application. Based on type, the market is classified as nonselective MAO-A inhibitors, selective MAO-B inhibitors, and nonselective MAO-B inhibitors. Based on application, the market is segmented as depression treatment, Parkinson's disease treatment, and others.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the reversible inhibitors of monoamine antidepressants market based on various segments. It also provides market size and forecast estimates from year 2019 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The reversible inhibitors of monoamine antidepressants market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting reversible inhibitors of monoamine antidepressants market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the reversible inhibitors of monoamine antidepressants market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the reversible inhibitors of monoamine antidepressants market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from reversible inhibitors of monoamine antidepressants market are anticipated to have lucrative growth opportunities in the future with the rising demand for reversible inhibitors of monoamine antidepressants in the global market. Below mentioned is the list of few companies engaged in the reversible inhibitors of monoamine antidepressants market.

The report also includes the profiles of key players in reversible inhibitors of monoamine antidepressants market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Alkermes plc
- Teva Pharmaceuticals Ltd
- Valeant Pharmaceuticals International Inc
- Takeda Pharmaceutical Company Ltd
- Eli Lilly & Company
- GlaxoSmithKline plc
- Pfizer, Inc.
- Bristol-Myers Squibb Company
- Merck & Co., Inc.
- H. Lundbeck A/S
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Reversible Inhibitors Of Monoamine Antidepressants Market - By Type
1.3.2 Reversible Inhibitors Of Monoamine Antidepressants Market - By Application
1.3.3 Reversible Inhibitors Of Monoamine Antidepressants Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. REVERSIBLE INHIBITORS OF MONOAMINE ANTIDEPRESSANTS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. REVERSIBLE INHIBITORS OF MONOAMINE ANTIDEPRESSANTS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. REVERSIBLE INHIBITORS OF MONOAMINE ANTIDEPRESSANTS MARKET - GLOBAL MARKET ANALYSIS
6.1. REVERSIBLE INHIBITORS OF MONOAMINE ANTIDEPRESSANTS - GLOBAL MARKET OVERVIEW
6.2. REVERSIBLE INHIBITORS OF MONOAMINE ANTIDEPRESSANTS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. REVERSIBLE INHIBITORS OF MONOAMINE ANTIDEPRESSANTS MARKET - REVENUE AND FORECASTS TO 2027 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. NONSELECTIVE MAO-A INHIBITORS
7.3.1. Overview
7.3.2. Nonselective MAO-A Inhibitors Market Forecast and Analysis
7.4. SELECTIVE MAO-B INHIBITORS
7.4.1. Overview
7.4.2. Selective MAO-B Inhibitors Market Forecast and Analysis
7.5. NONSELECTIVE MAO-B INHIBITORS
7.5.1. Overview
7.5.2. Nonselective MAO-B Inhibitors Market Forecast and Analysis
8. REVERSIBLE INHIBITORS OF MONOAMINE ANTIDEPRESSANTS MARKET - REVENUE AND FORECASTS TO 2027 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. DEPRESSION TREATMENT
8.3.1. Overview
8.3.2. Depression Treatment Market Forecast and Analysis
8.4. PARKINSON'S DISEASE TREATMENT
8.4.1. Overview
8.4.2. Parkinson's Disease Treatment Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. REVERSIBLE INHIBITORS OF MONOAMINE ANTIDEPRESSANTS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Reversible Inhibitors Of Monoamine Antidepressants Market Overview
9.1.2 North America Reversible Inhibitors Of Monoamine Antidepressants Market Forecasts and Analysis
9.1.3 North America Reversible Inhibitors Of Monoamine Antidepressants Market Forecasts and Analysis - By Type
9.1.4 North America Reversible Inhibitors Of Monoamine Antidepressants Market Forecasts and Analysis - By Application
9.1.5 North America Reversible Inhibitors Of Monoamine Antidepressants Market Forecasts and Analysis - By Countries
9.1.5.1 United States Reversible Inhibitors Of Monoamine Antidepressants Market
9.1.5.1.1 United States Reversible Inhibitors Of Monoamine Antidepressants Market by Type
9.1.5.1.2 United States Reversible Inhibitors Of Monoamine Antidepressants Market by Application
9.1.5.2 Canada Reversible Inhibitors Of Monoamine Antidepressants Market
9.1.5.2.1 Canada Reversible Inhibitors Of Monoamine Antidepressants Market by Type
9.1.5.2.2 Canada Reversible Inhibitors Of Monoamine Antidepressants Market by Application
9.1.5.3 Mexico Reversible Inhibitors Of Monoamine Antidepressants Market
9.1.5.3.1 Mexico Reversible Inhibitors Of Monoamine Antidepressants Market by Type
9.1.5.3.2 Mexico Reversible Inhibitors Of Monoamine Antidepressants Market by Application
9.2. EUROPE
9.2.1 Europe Reversible Inhibitors Of Monoamine Antidepressants Market Overview
9.2.2 Europe Reversible Inhibitors Of Monoamine Antidepressants Market Forecasts and Analysis
9.2.3 Europe Reversible Inhibitors Of Monoamine Antidepressants Market Forecasts and Analysis - By Type
9.2.4 Europe Reversible Inhibitors Of Monoamine Antidepressants Market Forecasts and Analysis - By Application
9.2.5 Europe Reversible Inhibitors Of Monoamine Antidepressants Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Reversible Inhibitors Of Monoamine Antidepressants Market
9.2.5.1.1 Germany Reversible Inhibitors Of Monoamine Antidepressants Market by Type
9.2.5.1.2 Germany Reversible Inhibitors Of Monoamine Antidepressants Market by Application
9.2.5.2 France Reversible Inhibitors Of Monoamine Antidepressants Market
9.2.5.2.1 France Reversible Inhibitors Of Monoamine Antidepressants Market by Type
9.2.5.2.2 France Reversible Inhibitors Of Monoamine Antidepressants Market by Application
9.2.5.3 Italy Reversible Inhibitors Of Monoamine Antidepressants Market
9.2.5.3.1 Italy Reversible Inhibitors Of Monoamine Antidepressants Market by Type
9.2.5.3.2 Italy Reversible Inhibitors Of Monoamine Antidepressants Market by Application
9.2.5.4 Spain Reversible Inhibitors Of Monoamine Antidepressants Market
9.2.5.4.1 Spain Reversible Inhibitors Of Monoamine Antidepressants Market by Type
9.2.5.4.2 Spain Reversible Inhibitors Of Monoamine Antidepressants Market by Application
9.2.5.5 United Kingdom Reversible Inhibitors Of Monoamine Antidepressants Market
9.2.5.5.1 United Kingdom Reversible Inhibitors Of Monoamine Antidepressants Market by Type
9.2.5.5.2 United Kingdom Reversible Inhibitors Of Monoamine Antidepressants Market by Application
9.2.5.6 Rest of Europe Reversible Inhibitors Of Monoamine Antidepressants Market
9.2.5.6.1 Rest of Europe Reversible Inhibitors Of Monoamine Antidepressants Market by Type
9.2.5.6.2 Rest of Europe Reversible Inhibitors Of Monoamine Antidepressants Market by Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Reversible Inhibitors Of Monoamine Antidepressants Market Overview
9.3.2 Asia-Pacific Reversible Inhibitors Of Monoamine Antidepressants Market Forecasts and Analysis
9.3.3 Asia-Pacific Reversible Inhibitors Of Monoamine Antidepressants Market Forecasts and Analysis - By Type
9.3.4 Asia-Pacific Reversible Inhibitors Of Monoamine Antidepressants Market Forecasts and Analysis - By Application
9.3.5 Asia-Pacific Reversible Inhibitors Of Monoamine Antidepressants Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Reversible Inhibitors Of Monoamine Antidepressants Market
9.3.5.1.1 Australia Reversible Inhibitors Of Monoamine Antidepressants Market by Type
9.3.5.1.2 Australia Reversible Inhibitors Of Monoamine Antidepressants Market by Application
9.3.5.2 China Reversible Inhibitors Of Monoamine Antidepressants Market
9.3.5.2.1 China Reversible Inhibitors Of Monoamine Antidepressants Market by Type
9.3.5.2.2 China Reversible Inhibitors Of Monoamine Antidepressants Market by Application
9.3.5.3 India Reversible Inhibitors Of Monoamine Antidepressants Market
9.3.5.3.1 India Reversible Inhibitors Of Monoamine Antidepressants Market by Type
9.3.5.3.2 India Reversible Inhibitors Of Monoamine Antidepressants Market by Application
9.3.5.4 Japan Reversible Inhibitors Of Monoamine Antidepressants Market
9.3.5.4.1 Japan Reversible Inhibitors Of Monoamine Antidepressants Market by Type
9.3.5.4.2 Japan Reversible Inhibitors Of Monoamine Antidepressants Market by Application
9.3.5.5 South Korea Reversible Inhibitors Of Monoamine Antidepressants Market
9.3.5.5.1 South Korea Reversible Inhibitors Of Monoamine Antidepressants Market by Type
9.3.5.5.2 South Korea Reversible Inhibitors Of Monoamine Antidepressants Market by Application
9.3.5.6 Rest of Asia-Pacific Reversible Inhibitors Of Monoamine Antidepressants Market
9.3.5.6.1 Rest of Asia-Pacific Reversible Inhibitors Of Monoamine Antidepressants Market by Type
9.3.5.6.2 Rest of Asia-Pacific Reversible Inhibitors Of Monoamine Antidepressants Market by Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Reversible Inhibitors Of Monoamine Antidepressants Market Overview
9.4.2 Middle East and Africa Reversible Inhibitors Of Monoamine Antidepressants Market Forecasts and Analysis
9.4.3 Middle East and Africa Reversible Inhibitors Of Monoamine Antidepressants Market Forecasts and Analysis - By Type
9.4.4 Middle East and Africa Reversible Inhibitors Of Monoamine Antidepressants Market Forecasts and Analysis - By Application
9.4.5 Middle East and Africa Reversible Inhibitors Of Monoamine Antidepressants Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Reversible Inhibitors Of Monoamine Antidepressants Market
9.4.5.1.1 South Africa Reversible Inhibitors Of Monoamine Antidepressants Market by Type
9.4.5.1.2 South Africa Reversible Inhibitors Of Monoamine Antidepressants Market by Application
9.4.5.2 Saudi Arabia Reversible Inhibitors Of Monoamine Antidepressants Market
9.4.5.2.1 Saudi Arabia Reversible Inhibitors Of Monoamine Antidepressants Market by Type
9.4.5.2.2 Saudi Arabia Reversible Inhibitors Of Monoamine Antidepressants Market by Application
9.4.5.3 Rest of Middle East and Africa Reversible Inhibitors Of Monoamine Antidepressants Market
9.4.5.3.1 Rest of Middle East and Africa Reversible Inhibitors Of Monoamine Antidepressants Market by Type
9.4.5.3.2 Rest of Middle East and Africa Reversible Inhibitors Of Monoamine Antidepressants Market by Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Reversible Inhibitors Of Monoamine Antidepressants Market Overview
9.5.2 South and Central America Reversible Inhibitors Of Monoamine Antidepressants Market Forecasts and Analysis
9.5.3 South and Central America Reversible Inhibitors Of Monoamine Antidepressants Market Forecasts and Analysis - By Type
9.5.4 South and Central America Reversible Inhibitors Of Monoamine Antidepressants Market Forecasts and Analysis - By Application
9.5.5 South and Central America Reversible Inhibitors Of Monoamine Antidepressants Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Reversible Inhibitors Of Monoamine Antidepressants Market
9.5.5.1.1 Brazil Reversible Inhibitors Of Monoamine Antidepressants Market by Type
9.5.5.1.2 Brazil Reversible Inhibitors Of Monoamine Antidepressants Market by Application
9.5.5.2 Argentina Reversible Inhibitors Of Monoamine Antidepressants Market
9.5.5.2.1 Argentina Reversible Inhibitors Of Monoamine Antidepressants Market by Type
9.5.5.2.2 Argentina Reversible Inhibitors Of Monoamine Antidepressants Market by Application
9.5.5.3 Rest of South and Central America Reversible Inhibitors Of Monoamine Antidepressants Market
9.5.5.3.1 Rest of South and Central America Reversible Inhibitors Of Monoamine Antidepressants Market by Type
9.5.5.3.2 Rest of South and Central America Reversible Inhibitors Of Monoamine Antidepressants Market by Application
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL REVERSIBLE INHIBITORS OF MONOAMINE ANTIDEPRESSANTS MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. REVERSIBLE INHIBITORS OF MONOAMINE ANTIDEPRESSANTS MARKET, KEY COMPANY PROFILES
12.1. ALKERMES PLC
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. TEVA PHARMACEUTICALS LTD
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. VALEANT PHARMACEUTICALS INTERNATIONAL INC
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. TAKEDA PHARMACEUTICAL COMPANY LTD
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. ELI LILLY AND COMPANY
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. GLAXOSMITHKLINE PLC
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. PFIZER, INC.
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. BRISTOL-MYERS SQUIBB COMPANY
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. MERCK AND CO., INC.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. H. LUNDBECK A/S
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Alkermes plc
2. Teva Pharmaceuticals Ltd
3. Valeant Pharmaceuticals International Inc
4. Takeda Pharmaceutical Company Ltd
5. Eli Lilly & Company
6. GlaxoSmithKline plc
7. Pfizer, Inc.
8. Bristol-Myers Squibb Company
9. Merck & Co., Inc.
10. H. Lundbeck A/S
TIPRE00018776
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking